Across TCGA pan-cancer cohorts, KIF26A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated KIF26A data layer compared with 26 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher KIF26A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KIF26A expression acts as an unfavorable survival marker.
GBM are the cancer types where KIF26A mass-spec protein most reproducibly stratifies survival.